Spineway 2021 Half Year results postponed following Distimp acquisition

Press release         Ecully6 September 2021 – 8:30 am

2021 Half Year Results postponed

Spineway, specialized in innovative implants for the treatment of severe disorders of the spinal column (spine), informs 2021 half year results are delayed due to the acquisition of Distimp, event that was not foreseen at the time the news agenda was published.

Originally planned for September the 6th after stock exchange closing, half year results will finally be communicated on September the 13th after stock exchange closing.

Upcoming13 September 2021 – 2021 Half year results

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).
ISIN: FR0011398874 – ALSPW        

Contacts :


Shareholder-services line

Available Tuesday through Thursday

(10 a.m. – 12 p.m.)

New number (no tax)

0806 70 60 60

Eligible PEA / PME


Euronext Growth


Finance & Communication

Investor relations

Solène Kennis

Print Friendly, PDF & Email

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button